Novo Nordisk’s CagriSema demonstrated superior HbA1c reduction and weight loss in adults with type 2 diabetes in the REIMAGINE 2 trial

Novo Nordisk has recently announced results from REIMAGINE 2, a phase 3 trial from the global REIMAGINE clinical trial programme. CagriSema demonstrated both superior HbA_1creduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial.

Note that REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema in two different doses compared to two different doses of semaglutide, cagrilintide and placebo. The trial included 2,728 people with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor.

In addition, when applying the treatment-regimen estimand, people treated with CagriSema 2.4 mg/2.4 mg achieved superior HbA_1c reduction of 1.80%-points after 68 weeks compared to 1.68%-points with semaglutide 2.4 mg. In addition, people treated with CagriSema 2.4 mg/2.4 mg achieved superior weight loss of 12.9% after 68 weeks compared to 9.2% with semaglutide 2.4 mg.

CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with incretin and amylin-based therapies.

“We are very pleased by the clinical profile of CagriSema in type 2 diabetes patients, including a confirmation of the very strong weight loss data seen with CagriSema in the obesity trials”, said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “By combining semaglutide and cagrilintide, we’re seeing superior outcomes in both blood glucose control and weight reduction beyond those achieved with each therapy individually. The results strengthen our belief that CagriSema could be the first amylin-based combination therapy and a promising treatment option for individuals with type 2 diabetes, who also has a focus on weight loss.”

---

---

Related Topics and Keywords

CagriSema, hba1c, REIMAGINE 2 trial, type 2 diabetes